BluGlass Limited (ASX: BLG), a global semiconductor developer, has received two purchase orders for gallium nitride (GaN) lasers from a quantum photonics pioneer and a leading medical device manufacturer. These orders cover BluGlass’ product suite of GaN lasers in wavelengths of 405nm, 420nm, and 450nm, and also include the first order for their early prototype of higher-powered 405nm 3W multi-mode lasers in flexible form factors.
Although the initial orders do not have a significant impact on the revenue, the company has already started fulfilling customer orders and is currently in advanced discussions with potential customers across its main market segments.
BluGlass CEO Jim Haden said, “Our lasers will be used for testing in novel quantum sensing and surgical applications. Our single-mode lasers in violet and blue wavelengths are increasingly sought after as they are ideal for biomedical, robotics, and quantum applications.
“We’re also experiencing strong interest in our advanced roadmaps and higher-powered lasers, securing the first order of 50 alpha 3W multi-mode violet prototypes for deployment in medical applications. Ongoing enhancements to our launched product offering are driving conversion efficiency and reliability improvements. If our alpha lasers test well, then once the Company moves to volume production of more mature devices, these customers have the potential to place large, recurring purchase orders for high-volume applications.”
